Multinational phase 2 trial of trastuzumab deruxtecan for HER2-overexpressing metastatic non-small cell lung cancer

The multinational phase 2 DESTINY-Lung01 trial evaluated trastuzumab deruxtecan (T-DXd) in patients with metastatic non-squamous non-small cell lung cancer with HER2-overexpression. In the T-DXd 6.4 mg/kg every three weeks cohort the ORR was 26.5% (95% CI 15.0-41.1) and in the T-DXd 5.4 mg/kg every three weeks cohort the ORR was 34.1% (20.1-50.6). Treatment-related adverse events of grade 3 or higher were seen in 39% of patients. The authors conclude that given the low antitumor activity of existing treatment options in this patient population, T-DXd might have the potential to fill a large unmet need in HER2-overexpressing metastatic non-small cell lung cancer.